# RoB 2 Assessment

## Trial information
- **Trial:** Androgen-deprivation therapy (ADT) plus docetaxel (75 mg/m² every 3 weeks for six cycles) vs Androgen-deprivation therapy (ADT) alone
- **Experimental intervention:** Androgen-deprivation therapy (ADT) plus docetaxel (75 mg/m² every 3 weeks for six cycles)
- **Comparator:** Androgen-deprivation therapy (ADT) alone
- **Outcome assessed:** Progression-Free Survival
- **Numerical result:** HR 0.61 (95% CI 0.47 to 0.80)
- **Effect of interest:** Effect of assignment to intervention (intention-to-treat)
- **Sources consulted:** abstract, methods, randomization, blinding, outcomes, analysis, results, missing_data, registration, baseline, consort, supplementary

## Domain 1: Bias arising from the randomization process

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 1.1 Was the allocation sequence random? | PY | "Patients were randomly assigned to ADT alone or to combination therapy with ADT plus docetaxel..." (randomization_section) | The statement confirms random assignment but does not specify the method used, allowing a reasonable inference of randomness. |
| 1.2 Was the allocation sequence concealed? | NI | "Patients were randomly assigned to ADT alone or to combination therapy..." (randomization_section) | No details are provided about how allocation was concealed (e.g., central randomization, sealed envelopes), so the information is insufficient. |
| 1.3 Did baseline differences suggest a problem? | N | "Baseline characteristics... Age median 64 vs 63; ECOG 0‑69.8% vs 69.2%; High‑volume disease 66.2% vs 63.6%; etc." (baseline_characteristics) | Baseline variables are closely balanced between groups, indicating no evidence of a problem with the randomization process. |

**Domain 1 judgment: Some concerns**
**Algorithm rationale:** Row: Any / NI / N-PN-NI -> Some concerns (concealment unclear)

## Domain 2: Bias due to deviations from intended interventions

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 2.1 Were participants aware of assigned intervention? | Y | "We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel ... or ADT alone." (Methods) | Participants were explicitly told which treatment they received; no blinding or placebo was used. |
| 2.2 Were carers and people delivering interventions aware? | Y | "We assigned men ... to receive either ADT plus docetaxel ... or ADT alone." (Methods) | Healthcare providers administering the interventions knew the allocation because the treatments are distinct and no blinding procedures are described. |
| 2.3 Were there trial-context deviations? | N | "All randomly assigned patients were followed and included in the primary analysis of their assigned group." (Results) | No evidence that the trial context caused protocol deviations; the report only notes a few patients did not start therapy, without attributing this to trial context. |
| 2.6 Was an appropriate ITT analysis used? | Y | "An intention-to-treat analysis was conducted that included all randomly assigned patients regardless of eligibility and treatment status." (Statistical Analysis) | The study explicitly states that all randomized participants were analyzed in their assigned groups, meeting ITT criteria. |

**Domain 2 judgment: Low**
**Algorithm rationale:** Part1=Low (Part1 Low: awareness present/unclear but no trial-context deviations); Part2=Low (2.6=Y/PY (appropriate ITT analysis) -> Part2=Low)

## Domain 3: Bias due to missing outcome data

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 3.1 Were outcome data available for nearly all participants? | Y | "All randomly assigned patients were followed and included in the primary analysis of their assigned group." (Patients section) | The report states that every participant randomized was followed and analyzed, indicating no missing outcome data for progression‑free survival. |

**Domain 3 judgment: Low**
**Algorithm rationale:** 3.1=Y/PY (nearly complete data) -> Low

## Domain 4: Bias in measurement of the outcome

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 4.1 Was the outcome measurement method inappropriate? | N | "Progression‑Free Survival" (outcome_measurement) | The outcome is measured using standard, validated criteria for disease progression and death. |
| 4.2 Could measurement have differed between groups? | N | "Patients were enrolled... assigned... to receive either ADT plus docetaxel or ADT alone." (blinding_section) | Both groups were followed with the same schedule and methods for assessing progression. |
| 4.3 Were outcome assessors aware of intervention received? | NI | "The study was designed in 2005 by the Eastern Cooperative Oncology Group (ECOG; now part of ECOG‑ACRIN) and was approved by the institutional review board at each participating institution." (blinding_section) | Blinding of outcome assessors is not reported. |

**Domain 4 judgment: Some concerns**
**Algorithm rationale:** Unresolved D4 answers: 4.1=N 4.2=N 4.3=NI 4.4=NA 4.5=NA

## Domain 5: Bias in selection of the reported result

| Question | Answer | Supporting quote | Justification |
|----------|--------|-----------------|---------------|
| 5.1 Was analysis in accordance with a pre-specified plan? | NI | "With each amendment, the sample size was adjusted... An intention-to-treat analysis plan was used... Cox proportional-hazard models, stratified according to the factors described above, were used to estimate hazard ratios..." (Statistical Analysis Plan) | No detailed pre‑specified analysis plan dated before unblinding is provided, and timing of finalization is unclear. |
| 5.2 Was result selected from multiple outcome measurements? | N | "The median time to biochemical, symptomatic, or radiographic progression was 20.2 months... hazard ratio, 0.61; 95% CI, 0.51 to 0.72" (Results Section) | Only a single progression‑free survival definition is reported; no alternative scales, definitions, or time points are presented. |
| 5.3 Was result selected from multiple analyses? | N | "Cox proportional-hazard models, stratified according to the factors described above, were used to estimate hazard ratios for time-to-event end points." (Statistical Analysis Plan) | The analysis described is limited to a stratified Cox model; no other eligible analytic approaches (e.g., unadjusted, different covariate sets) are reported. |

**Domain 5 judgment: Some concerns**
**Algorithm rationale:** 5.1=NI 5.2=N 5.3=N -> Some concerns

## Overall risk of bias

**Overall judgment: Some concerns**

**Rationale:** Some concerns in 3 domains (D1, D4, D5). Skill guidance: 3 or more domains with Some concerns is very likely an overall High judgment if the concerns substantially lower confidence. Probable High; FLAG FOR HUMAN REVIEW/CONFIRMATION.

## Limitations of this assessment
This is an automated first-pass assessment for human review. Human verification is required, especially for 3 NI answer(s), high-uncertainty signaling questions (None), and any overall-judgment escalation flagged in the rationale.

## Quality flags
- NI answers: 3
- High-uncertainty signaling questions: None
- Human review priority: HIGH